Shopping Cart 0
Cart Subtotal
USD 0

Thalassemia - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000

Details

Thalassemia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia-Pipeline Review, H2 2018, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 7, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Thalassemia-Overview 6

Thalassemia-Therapeutics Development 7

Thalassemia-Therapeutics Assessment 15

Thalassemia-Companies Involved in Therapeutics Development 25

Thalassemia-Drug Profiles 35

Thalassemia-Dormant Projects 143

Thalassemia-Discontinued Products 144

Thalassemia-Product Development Milestones 145

Appendix 158


List Of Figure

List of Figures

Number of Products under Development for Thalassemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Thalassemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Thalassemia-Pipeline by Acceleron Pharma Inc, H2 2018

Thalassemia-Pipeline by Agios Pharmaceuticals Inc, H2 2018

Thalassemia-Pipeline by bluebird bio Inc, H2 2018

Thalassemia-Pipeline by Cadila Healthcare Ltd, H2 2018

Thalassemia-Pipeline by Calimmune Inc, H2 2018

Thalassemia-Pipeline by CRISPR Therapeutics, H2 2018

Thalassemia-Pipeline by Editas Medicine Inc, H2 2018

Thalassemia-Pipeline by Errant Gene Therapeutics LLC, H2 2018

Thalassemia-Pipeline by Gamida Cell Ltd, H2 2018

Thalassemia-Pipeline by Gilead Sciences Inc, H2 2018

Thalassemia-Pipeline by Incyte Corp, H2 2018

Thalassemia-Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Thalassemia-Pipeline by Kiadis Pharma NV, H2 2018

Thalassemia-Pipeline by La Jolla Pharmaceutical Company, H2 2018

Thalassemia-Pipeline by Merck & Co Inc, H2 2018

Thalassemia-Pipeline by Poseida Therapeutics Inc, H2 2018

Thalassemia-Pipeline by Protagonist Therapeutics Inc, H2 2018

Thalassemia-Pipeline by Sangamo Therapeutics Inc, H2 2018

Thalassemia-Pipeline by Silence Therapeutics Plc, H2 2018

Thalassemia-Pipeline by Vifor Pharma AG, H2 2018

Thalassemia-Dormant Projects, H2 2018

Thalassemia-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Thalassemia Therapeutic Products under Development, Key Players in Thalassemia Therapeutics, Thalassemia Pipeline Overview, Thalassemia Pipeline, Thalassemia Pipeline Assessment


Companies

Acceleron Pharma Inc

Agios Pharmaceuticals Inc

bluebird bio Inc

Cadila Healthcare Ltd

Calimmune Inc

CRISPR Therapeutics

Editas Medicine Inc

Errant Gene Therapeutics LLC

Gamida Cell Ltd

Gilead Sciences Inc

Incyte Corp

Ionis Pharmaceuticals Inc

Kiadis Pharma NV

La Jolla Pharmaceutical Company

Merck & Co Inc

Poseida Therapeutics Inc

Protagonist Therapeutics Inc

Sangamo Therapeutics Inc

Silence Therapeutics Plc

Vifor Pharma AG

Company Profile

Company Profile Title

Thalassemia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thalassemia-Pipeline Review, H2 2018, provides an overview of the Thalassemia (Hematological Disorders) pipeline landscape.

Thalassemia is a group of inherited blood disorders that affect the body's ability to produce hemoglobin and red blood cells. Symptoms include fussiness, paleness, frequent infections, failure to thrive, poor appetite and jaundice. Predisposing factors include family history. Treatment includes blood transfusions and bone marrow transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thalassemia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thalassemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thalassemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Thalassemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 10, 7, 13 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 1 molecules, respectively.

Thalassemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thalassemia (Hematological Disorders).

- The pipeline guide reviews pipeline therapeutics for Thalassemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thalassemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thalassemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thalassemia (Hematological Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thalassemia (Hematological Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thalassemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Thalassemia-Overview 6

Thalassemia-Therapeutics Development 7

Thalassemia-Therapeutics Assessment 15

Thalassemia-Companies Involved in Therapeutics Development 25

Thalassemia-Drug Profiles 35

Thalassemia-Dormant Projects 143

Thalassemia-Discontinued Products 144

Thalassemia-Product Development Milestones 145

Appendix 158


List Of Figure

List of Figures

Number of Products under Development for Thalassemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Thalassemia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Thalassemia-Pipeline by Acceleron Pharma Inc, H2 2018

Thalassemia-Pipeline by Agios Pharmaceuticals Inc, H2 2018

Thalassemia-Pipeline by bluebird bio Inc, H2 2018

Thalassemia-Pipeline by Cadila Healthcare Ltd, H2 2018

Thalassemia-Pipeline by Calimmune Inc, H2 2018

Thalassemia-Pipeline by CRISPR Therapeutics, H2 2018

Thalassemia-Pipeline by Editas Medicine Inc, H2 2018

Thalassemia-Pipeline by Errant Gene Therapeutics LLC, H2 2018

Thalassemia-Pipeline by Gamida Cell Ltd, H2 2018

Thalassemia-Pipeline by Gilead Sciences Inc, H2 2018

Thalassemia-Pipeline by Incyte Corp, H2 2018

Thalassemia-Pipeline by Ionis Pharmaceuticals Inc, H2 2018

Thalassemia-Pipeline by Kiadis Pharma NV, H2 2018

Thalassemia-Pipeline by La Jolla Pharmaceutical Company, H2 2018

Thalassemia-Pipeline by Merck & Co Inc, H2 2018

Thalassemia-Pipeline by Poseida Therapeutics Inc, H2 2018

Thalassemia-Pipeline by Protagonist Therapeutics Inc, H2 2018

Thalassemia-Pipeline by Sangamo Therapeutics Inc, H2 2018

Thalassemia-Pipeline by Silence Therapeutics Plc, H2 2018

Thalassemia-Pipeline by Vifor Pharma AG, H2 2018

Thalassemia-Dormant Projects, H2 2018

Thalassemia-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Thalassemia Therapeutic Products under Development, Key Players in Thalassemia Therapeutics, Thalassemia Pipeline Overview, Thalassemia Pipeline, Thalassemia Pipeline Assessment


Companies

Acceleron Pharma Inc

Agios Pharmaceuticals Inc

bluebird bio Inc

Cadila Healthcare Ltd

Calimmune Inc

CRISPR Therapeutics

Editas Medicine Inc

Errant Gene Therapeutics LLC

Gamida Cell Ltd

Gilead Sciences Inc

Incyte Corp

Ionis Pharmaceuticals Inc

Kiadis Pharma NV

La Jolla Pharmaceutical Company

Merck & Co Inc

Poseida Therapeutics Inc

Protagonist Therapeutics Inc

Sangamo Therapeutics Inc

Silence Therapeutics Plc

Vifor Pharma AG